Home Featured Page 259

Featured

Latest

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of Psychedelic Action

Small Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study...

PT246 – Amber and Marcus Capone of VETS – Foundational Healing...

MYND Life Sciences announces Depression Biomarker Diagnostic Program

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to...

Can Psychedelics Help Heal Moral Injury?

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed...

MindMed announces shareholder Meeting Results

PTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler

MYND Life Sciences Inc. Establishes Scientific Advisory Board

EDITOR PICKS

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of Psychedelic Action

Small Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study...

PT246 – Amber and Marcus Capone of VETS – Foundational Healing...

MYND Life Sciences announces Depression Biomarker Diagnostic Program

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to...

Can Psychedelics Help Heal Moral Injury?

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed...

MindMed announces shareholder Meeting Results

PTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler

MYND Life Sciences Inc. Establishes Scientific Advisory Board

EDITOR PICKS

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY